Novel methods of treating bone diseases or disorders are provided.
1-Pyrimidinyloxy-3-hetaryl-alkylamino-2-propanols
申请人:Mead Johnson & Company
公开号:US04517188A1
公开(公告)日:1985-05-14
1-(4-Pyrimidinyloxy)-3-(hetarylalkylamino)-2-propanols are cardiovascular agents having a range of vasodilator and adrenergic beta-receptor blocking activities making these compounds useful anti-hypertensive agents. Preferred compounds bear a hydrazino or hydrazono substituent in the 2- position of the pyrimidine ring.